These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36967026)

  • 1. Use of Utility and Disability Weights in Economic Evaluation of Pediatric Vaccines.
    Neppelenbroek NJM; de Wit GA; Dalziel K; Devlin N; Carvalho NI
    Value Health; 2023 Jul; 26(7):1098-1106. PubMed ID: 36967026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sources and Characteristics of Utility Weights for Economic Evaluation of Pediatric Vaccines: A Systematic Review.
    Herdman M; Cole A; Hoyle CK; Coles V; Carroll S; Devlin N
    Value Health; 2016; 19(2):255-66. PubMed ID: 27021761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the Choice of Health Metric, DALY or QALY, Influence Conclusions of Health Economic Evaluation? A Case Study of Rotavirus Vaccine in Burundi.
    Niyibitegeka F; Thavorncharoensap M; Riewpaiboon A; Youngkong S
    Appl Health Econ Health Policy; 2022 Sep; 20(5):707-716. PubMed ID: 35469393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ignored and undervalued in public health: a systematic review of health state utility values associated with syphilis infection.
    Miao P; Terris-Prestholt F; Fairley CK; Tucker JD; Wiseman V; Mayaud P; Zhang Y; Rowley J; Gottlieb S; Korenromp EL; Watts CG; Ong JJ
    Health Qual Life Outcomes; 2024 Feb; 22(1):17. PubMed ID: 38350925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using QALYs versus DALYs to measure cost-effectiveness: How much does it matter?
    Feng X; Kim DD; Cohen JT; Neumann PJ; Ollendorf DA
    Int J Technol Assess Health Care; 2020 Apr; 36(2):96-103. PubMed ID: 32340631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global Patterns of QALY and DALY Use in Surgical Cost-Utility Analyses: A Systematic Review.
    Rios-Diaz AJ; Lam J; Ramos MS; Moscoso AV; Vaughn P; Zogg CK; Caterson EJ
    PLoS One; 2016; 11(2):e0148304. PubMed ID: 26862894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring the Benefits of Healthcare: DALYs and QALYs - Does the Choice of Measure Matter? A Case Study of Two Preventive Interventions.
    Augustovski F; Colantonio LD; Galante J; Bardach A; Caporale JE; Zárate V; Chuang LH; Pichon-Riviere A; Kind P
    Int J Health Policy Manag; 2018 Feb; 7(2):120-136. PubMed ID: 29524936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of QALY weights for QALY calculations: a review of industry submissions requesting listing on the Australian Pharmaceutical Benefits Scheme 2002-4.
    Scuffham PA; Whitty JA; Mitchell A; Viney R
    Pharmacoeconomics; 2008; 26(4):297-310. PubMed ID: 18370565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative analysis.
    Holubar M; Stavroulakis MC; Maldonado Y; Ioannidis JP; Contopoulos-Ioannidis D
    PLoS One; 2017; 12(3):e0172414. PubMed ID: 28249046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses.
    Tomeny EM; Hampton T; Tran PB; Rosu L; Phiri MD; Haigh KA; Nidoi J; Wingfield T; Worrall E
    Pharmacoeconomics; 2024 Aug; ():. PubMed ID: 39110388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review.
    Ruiz-Negrón N; Menon J; King JB; Ma J; Bellows BK
    Pharmacoeconomics; 2019 May; 37(5):669-688. PubMed ID: 30637713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disability-Adjusted Life Years Due to Pediatric Out-of-Hospital Cardiac Arrest in the United States: A CARES Surveillance Group Study.
    Coute RA; Nathanson BH; DeMasi S; Mader TJ; Kurz MC;
    Circ Cardiovasc Qual Outcomes; 2023 May; 16(5):e009786. PubMed ID: 37192281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review of health economic studies in cranial neurosurgery.
    Ryu WHA; Yang MMH; Muram S; Jacobs WB; Casha S; Riva-Cambrin J
    Neurosurg Focus; 2018 May; 44(5):E2. PubMed ID: 29712519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive league table of cost-utility ratios: A systematic review of cost-effectiveness evidence for health policy decisions in India.
    Shah K; Singh M; Kotwani P; Tyagi K; Pandya A; Saha S; Saxena D; Rajshekar K
    Front Public Health; 2022; 10():831254. PubMed ID: 36311623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines.
    Silver MC; Neumann PJ; Ma S; Kim DD; Cohen JT; Nyaku M; Roberts C; Sinha A; Ollendorf DA
    Vaccine; 2021 Nov; 39(46):6727-6734. PubMed ID: 34656380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Burden of infectious disease studies in Europe and the United Kingdom: a review of methodological design choices.
    Charalampous P; Haagsma JA; Jakobsen LS; Gorasso V; Noguer I; Padron-Monedero A; Sarmiento R; Santos JV; McDonald SA; Plass D; Wyper GMA; Assunção R; von der Lippe E; Ádám B; AlKerwi A; Arabloo J; Baltazar AL; Bikbov B; Borrell-Pages M; Brus I; Burazeri G; Chaintoutis SC; Chen-Xu J; Chkhaberidze N; Cilovic-Lagarija S; Corso B; Cuschieri S; Di Bari C; Dopelt K; Economou M; Emeto TI; Fantke P; Fischer F; Freitas A; García-González JM; Gazzelloni F; Gissler M; Gkitakou A; Gulmez H; Gunes S; Haller S; Haneef R; Hincapié CA; Hynds P; Idavain J; Ilic M; Ilic I; Isola G; Kabir Z; Kamusheva M; Kolkhir P; Konar NM; Kostoulas P; Kulimbet M; La Vecchia C; Lauriola P; Levi M; Majer M; Mechili EA; Monasta L; Mondello S; Muñoz Laguna J; Nena E; Ng ESW; Nguewa P; Niranjan V; Nola IA; O'Caoimh R; Obradović M; Pallari E; Peyroteo M; Pinheiro V; Pranjic N; Reina Ortiz M; Riva S; Santoso CMA; Santric Milicevic M; Schmitt T; Speybroeck N; Sprügel M; Steiropoulos P; Stevanovic A; Thygesen LC; Tozija F; Unim B; Bektaş Uysal H; Varga O; Vasic M; Vieira RJ; Yigit V; Devleesschauwer B; Pires SM
    Epidemiol Infect; 2023 Jan; 151():e19. PubMed ID: 36621004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total hip replacement and surface replacement for the treatment of pain and disability resulting from end-stage arthritis of the hip (review of technology appraisal guidance 2 and 44): systematic review and economic evaluation.
    Clarke A; Pulikottil-Jacob R; Grove A; Freeman K; Mistry H; Tsertsvadze A; Connock M; Court R; Kandala NB; Costa M; Suri G; Metcalfe D; Crowther M; Morrow S; Johnson S; Sutcliffe P
    Health Technol Assess; 2015 Jan; 19(10):1-668, vii-viii. PubMed ID: 25634033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.